For equal-efficiency qPCR assays, sample X crosses threshold two cycles before sample Y. Approximately how much more starting target is in X?
A about twice as little
B about sixteen times less
C about four times as much
D the same amount
Answer: C. about four times as much. With near-100% amplification efficiency, each cycle represents roughly a twofold change, so two cycles correspond to about fourfold.
In 1,000 people, disease prevalence is 1%; a test has 99% sensitivity and 95% specificity. Its positive predictive value is closest to
A 95%
B 50%
C 99%
D 17%
Answer: D. 17%. About 10 people have disease and nearly all test positive; about 50 of 990 without disease test positive, so PPV is about 10/(10+50), or 17%.
A sandwich ELISA gives a weak signal even though target antigen is present. The capture and detection antibodies bind overlapping sites. What is a likely effect?
A the capture antibody turns into a reporter gene
B the test becomes a Western blot
C the assay will amplify the antigen DNA
D the detection antibody may be blocked from binding
Answer: D. the detection antibody may be blocked from binding. Overlapping epitopes can prevent simultaneous binding of capture and detection antibodies and reduce signal.
A CAR recognizes a surface antigen on a tumor cell. How does this recognition differ from a conventional T-cell receptor?
A a CAR is an antibody secreted into plasma
B a CAR can bind an intact surface target without peptide presentation by MHC
C a CAR binds only DNA in the nucleus
D a T-cell receptor never recognizes peptides
Answer: B. a CAR can bind an intact surface target without peptide presentation by MHC. A CAR uses an antibody-derived binding domain to recognize surface targets without the standard peptide-MHC restriction of a TCR.
A genome-editing therapy shows the intended edit in a target gene. Which evaluation is still needed?
A assume every edit is safe because the target was corrected
B measure only the target protein color
C assess unintended edits and relevant cell function using suitable methods
D skip genomic quality checks after editing
Answer: C. assess unintended edits and relevant cell function using suitable methods. Intended on-target editing does not rule out off-target changes or functional consequences.
A cell therapy uses a patient’s cells collected, modified, and returned. What is a central advantage of this approach?
A the product can be tailored to that patient’s cells
B it guarantees lifelong benefit
C it removes all immune reactions
D it eliminates every manufacturing risk
Answer: A. the product can be tailored to that patient’s cells. Autologous products are patient-specific, although they still require rigorous manufacturing and safety control.
An mRNA vaccine’s active instruction is translated in the cytoplasm. Which component supplies the encoded antigen information?
A the mRNA sequence
B the lipid nanoparticle alone
C the patient’s antibody genes
D the syringe needle
Answer: A. the mRNA sequence. The mRNA encodes the antigen; delivery formulation helps protect and transport it into cells.
A molecular test has excellent analytical performance in a lab but fails in a new clinic because samples are poorly collected. What is the main lesson?
A sample collection cannot affect results
B analytical sensitivity guarantees clinical utility
C pre-analytic handling is part of overall test performance
D the assay should be judged only by its primer sequence
Answer: C. pre-analytic handling is part of overall test performance. Collection, transport, and processing can affect a test even when the analytic method is sound.
A medical test detects a biomarker associated with disease but not the cause itself. What wording is appropriate?
A the result establishes an inherited mutation
B the test replaces all clinical evaluation
C the result supports assessment but is not alone a definitive diagnosis
D the biomarker proves causation
Answer: C. the result supports assessment but is not alone a definitive diagnosis. A biomarker may support evaluation but interpretation depends on validation and clinical context.
A patient has a germline variant and a tumor-specific variant in separate samples. Which approach helps distinguish them?
A measure cell viability
B test only the tumor and assume inheritance
C compare tumor DNA with matched normal DNA
D use antibody ELISA for both sequences
Answer: C. compare tumor DNA with matched normal DNA. Matched normal tissue helps separate inherited variants from tumor-acquired changes.
A therapy’s effect depends on a patient’s tumor antigen expression. Which test can help assess the target protein in tissue?
A PCR of an unrelated housekeeping gene only
B immunohistochemistry with a validated antibody
C a semen motility test
D a plant tissue culture assay
Answer: B. immunohistochemistry with a validated antibody. Immunohistochemistry can localize a protein target in tissue using a specific antibody.
A laboratory wants to confirm a specific protein’s presence and apparent molecular size after separation. Which method fits?
A DNA microarray
B ELISA for antibodies only
C Western blot
D RT-qPCR
Answer: C. Western blot. Western blot combines protein separation by size with antibody-based detection.
A point-of-care biosensor must convert analyte binding into an electronic readout. Which component performs the conversion?
A transducer
B capture antigen
C culture flask
D PCR primer
Answer: A. transducer. The transducer converts a biological recognition event into a measurable signal.
A clinical sequencing result has low read depth at a variant site. What is the concern?
A the sample contains no chromosomes
B the variant is automatically pathogenic
C the call may be less reliable and may need confirmation
D the result proves the patient is healthy
Answer: C. the call may be less reliable and may need confirmation. Low coverage can reduce confidence in variant detection and interpretation.
A companion diagnostic is developed alongside a targeted therapy. Its purpose is to
A produce the drug in a fermenter
B make every patient respond identically
C replace the therapy’s quality testing
D identify patients or samples with a biomarker relevant to treatment
Answer: D. identify patients or samples with a biomarker relevant to treatment. Companion diagnostics assess a relevant biomarker to guide use of a targeted treatment.
A cell product is contaminated with endotoxin from bacterial material. Which quality issue is present?
A an antibody titer
B a beneficial potency marker
C a genetic variant in the patient
D a safety impurity requiring control
Answer: D. a safety impurity requiring control. Endotoxin is a contaminant that can trigger harmful responses and must be controlled in relevant products.
An assay yields different results on repeated runs of the same reference sample. What should be checked first?
A precision, calibration, reagents, and operator or instrument variation
B the patient’s family history only
C the gene’s evolutionary origin
D whether the sample was transgenic
Answer: A. precision, calibration, reagents, and operator or instrument variation. Reproducibility requires consistent calibration and control of technical variation.
A clinical team uses a molecular test result to guide care. What is needed beyond analytical accuracy?
A clinical validation and evidence that the result is useful for the intended decision
B an unrelated animal model
C a larger sample label
D a brighter fluorescent dye only
Answer: A. clinical validation and evidence that the result is useful for the intended decision. Clinical validity and utility are distinct from analytical detection and must be established for the intended use.
A molecular diagnostic test is designed to detect one known mutation. Which probe or primer design is most important?
A a broad antibody against all proteins
B sequence complementarity to the variant and nearby target region
C an enzyme that digests every DNA molecule
D an unrelated promoter
Answer: B. sequence complementarity to the variant and nearby target region. Assay specificity depends on primers or probes designed to distinguish the target sequence from alternatives.
A biopharmaceutical product is made in living cells and shows batch-to-batch variation. What is an important response?
A validate process controls and characterize product quality
B skip purification testing
C assume all batches are identical because the DNA is identical
D measure only the culture color
Answer: A. validate process controls and characterize product quality. Biological production requires process control and product characterization to manage variability.
A patient has a disease-associated protein in plasma. Which approach can quantify that protein using an antigen-specific antibody and a standard curve?
A karyotyping
B ELISA
C DNA microarray
D PCR
Answer: B. ELISA. A calibrated ELISA can quantify an antigen by comparing signal with standards.
A sample is tested for HIV antibodies using an antigen-coated plate and a labeled anti-human immunoglobulin. This is
A flow sorting
B indirect ELISA
C Western blot
D RT-PCR
Answer: B. indirect ELISA. The patient’s antibody binds plate antigen, then labeled anti-human immunoglobulin detects it in an indirect ELISA.
A vaccine uses an mRNA instruction rather than a purified antigen. What happens after delivery?
A the mRNA becomes a chromosome in every cell
B the mRNA directly edits the immune-cell genome
C the vaccine contains a complete infectious pathogen
D some cells translate the mRNA into antigen
Answer: D. some cells translate the mRNA into antigen. Delivered mRNA can be translated into antigen that is presented to the immune system.
A gene-therapy study targets muscle cells and excludes reproductive cells. Which concern is reduced by this design?
A need for vector testing
B passing the modification to future generations
C variation in gene expression
D immune response in the treated person
Answer: B. passing the modification to future generations. Somatic targeting avoids intended germline modification and inheritance by offspring.
A diagnostic assay is highly sensitive but has limited specificity. What is a likely consequence?
A more false-negative results among every infected person
B guaranteed detection of the cause
C no positives in the patient group
D more false-positive results among people without the target condition
Answer: D. more false-positive results among people without the target condition. Low specificity means more nontarget samples may test positive, depending on prevalence and thresholds.